Lupus and the inhibitory dual receptor hypothesis
狼疮和抑制性双受体假说
基本信息
- 批准号:7949591
- 负责人:
- 金额:$ 17.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-06-07 至 2011-01-14
- 项目状态:已结题
- 来源:
- 关键词:AgonistAnti-Inflammatory AgentsAnti-inflammatoryAntibodiesAntigen-Antibody ComplexApoptoticAutoantibodiesAutoimmune DiseasesAutoimmune ProcessAutoimmunityBlocking AntibodiesCardiolipinsCell ExtractsCell membraneCellsCessation of lifeClinicalComplementComplement 1qComplexDNADendritic CellsDendritic cell activationDevelopmentDiseaseDisease ProgressionFamilyFc ReceptorGlomerulonephritisGlycoproteinsHematological DiseaseHumanImmuneImmunoglobulin GImmunoglobulin MIn VitroInflammatoryInflammatory ResponseInvestigationKidneyKidney DiseasesLupusMAP Kinase GeneMannose Binding LectinMannose-Binding LectinsMediatingMembraneMicroscopyModelingMusNecrosisNuclear AntigensPathogenesisPathologicPathway interactionsPatientsPhagocytesPhysiologicalPropertyRNAReceptor CellReceptor Protein-Tyrosine KinasesReceptor SignalingRegulationReportingRoleSignal Transduction PathwaySystemSystemic Lupus ErythematosusTLR7 geneTestingToll-like receptorsanti-IgMcell typeglomerular basement membranein vivoinsightmacrophagenovel therapeutic interventionprogramspublic health relevancereceptorresponse
项目摘要
DESCRIPTION (provided by applicant): We will investigate our newly developed inhibitory dual receptor hypothesis regarding the properties of autoantibodies to apoptotic cell membrane (ACM) determinants, which selectively discriminate cells dying from apoptotic death from healthy cells. We have discovered that anti-ACM antibodies form immune complexes with apoptotic cells that trigger anti-inflammatory signal transduction pathways. Therefore, our studies will characterize the mechanistic features by which ACM antibodies are postulated to enhance interactions with dual sets of inhibitory receptor; for early complement factors and for apoptotic cells. In particular, our investigations point to a critical interaction with the TAM family of receptor tyrosine kinases. To understand the greater relevance to pathogenesis, we will also investigate whether and how anti-ACM antibodies block the pro-inflammatory effects of pathogenic IgG autoantibodies to nuclear antigens, postulated to trigger TLR7 and TLR9. We will be characterize and visualize the in vitro inhibitory effects for IgG-nuclear antigen complexes, and we will also study their immune modulatory properties on the in vivo disease activity in murine models of autoimmune glomerulonephritis. Moreover, to investigate the relevance to clinical disease, we will also assess whether there is a correlation between levels in SLE patients of IgM and IgG subclass-specific anti-ACM autoantibodies and with lupus- associated autoantibodies, and with protection from certain features of lupus clinical disease activity. We anticipate that these studies will reveal new insights into immune regulation and autoimmune pathogenesis, and provide the essential bridge from basic studies to the development of a new therapeutic approach to the treatment of SLE.
PUBLIC HEALTH RELEVANCE: We will investigate how certain naturally occurring antibodies to dying cells can interact with cell receptors and trigger anti-inflammatory signal transduction pathways. We will also look for such effects in patients with systemic lupus erythematosus.
描述(由申请人提供):我们将研究我们新开发的抑制性双受体假说,该假说涉及针对凋亡细胞膜(ACM)决定因素的自身抗体的特性,该决定因素选择性地区分死于凋亡性死亡的细胞和健康细胞。我们发现,抗ACM抗体与凋亡细胞形成免疫复合体,触发抗炎信号转导通路。因此,我们的研究将描述ACM抗体增强与双重抑制受体、早期补体因子和凋亡细胞相互作用的机制。特别是,我们的研究指出了与受体酪氨酸激酶家族的关键相互作用。为了了解与发病机制的更大相关性,我们还将调查抗ACM抗体是否以及如何阻断致病性核抗原自身抗体的促炎作用,推测这种抗体可能触发TLR7和TLR9。我们将对免疫球蛋白-核抗原复合体的体外抑制作用进行表征和可视化,并研究其对自身免疫性肾炎小鼠体内疾病活动性的免疫调节作用。此外,为了探讨与临床疾病的相关性,我们还将评估SLE患者的IgM和Ig G亚类特异性抗ACM自身抗体和狼疮相关自身抗体之间是否存在相关性,以及与狼疮临床疾病活动的某些特征的保护作用之间是否存在相关性。我们期待这些研究将揭示免疫调节和自身免疫发病机制的新见解,并提供从基础研究到开发新的治疗方法治疗SLE的重要桥梁。
公共卫生相关性:我们将研究某些自然产生的针对濒死细胞的抗体如何与细胞受体相互作用,并触发抗炎信号转导途径。我们还将在系统性红斑狼疮患者中寻找这种影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gregg Joshua Silverman其他文献
Gregg Joshua Silverman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gregg Joshua Silverman', 18)}}的其他基金
Project 2: Microbiome pathobionts and Lupus pathogenesis
项目2:微生物组病原体和狼疮发病机制
- 批准号:
10004506 - 财政年份:2017
- 资助金额:
$ 17.77万 - 项目类别:
Project 2: Microbiome pathobionts and Lupus pathogenesis
项目2:微生物组病原体和狼疮发病机制
- 批准号:
10249215 - 财政年份:2017
- 资助金额:
$ 17.77万 - 项目类别:
Cell Death and Antibody-Mediated Protection from Autoimmunity
细胞死亡和抗体介导的自身免疫保护
- 批准号:
8264838 - 财政年份:2011
- 资助金额:
$ 17.77万 - 项目类别:
Lupus and the inhibitory dual receptor hypothesis
狼疮和抑制性双受体假说
- 批准号:
8082626 - 财政年份:2010
- 资助金额:
$ 17.77万 - 项目类别:
Lupus and the inhibitory dual receptor hypothesis
狼疮和抑制性双受体假说
- 批准号:
8260092 - 财政年份:2010
- 资助金额:
$ 17.77万 - 项目类别:
Lupus and the inhibitory dual receptor hypothesis
狼疮和抑制性双受体假说
- 批准号:
8473772 - 财政年份:2010
- 资助金额:
$ 17.77万 - 项目类别:
Lupus and the inhibitory dual receptor hypothesis
狼疮和抑制性双受体假说
- 批准号:
8306272 - 财政年份:2010
- 资助金额:
$ 17.77万 - 项目类别:
Cell Death and Antibody-Mediated Protection from Autoimmunity
细胞死亡和抗体介导的自身免疫保护
- 批准号:
7892627 - 财政年份:2009
- 资助金额:
$ 17.77万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 17.77万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 17.77万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 17.77万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 17.77万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 17.77万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 17.77万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 17.77万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 17.77万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 17.77万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 17.77万 - 项目类别: